On 30 September 2025, at the European Respiratory Society (ERS) Conference, held in Amsterdam, the Netherlands, Insmed presented results from a subgroup analysis from the Phase III ASPEN study ...

Seralutinib shows potential benefit in high-risk pulmonary arterial hypertension subgroups; safety data note cough and liver enzyme elevations as risks.

This article was adapted from STAT’s latest report, “Subgroup analysis: how to evaluate post hoc tests for significance in failed clinical trials.” Clinical trials of newly developed drugs often don’t ...

The MarketWatch News Department was not involved in the creation of this content. EORTC QLQ-C30 subgroup results confirm broad and durable quality-of-life improvements across disease stages and ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic neuroendocrine ...

Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — In this video, Toni K. Choueiri, MD, gives a summary of a subgroup analysis of the KEYNOTE-564 ...

Myosteatosis on computed tomography as a predictor of therapeutic response to CDK4/6 inhibitors plus aromatase inhibitors in patients with advanced breast cancer. Subgroup OS HR (95% CI) OS p-value ...

Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025 – CABOMETYX ...

These subgroup analyses add to the existing evidence of bempedoic acid as an effective treatment for the reduction of cardiovascular risk. MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Europe GmbH ...

Increased diversity in clinical trials remains an unmet need, and in the new SEQUOIA trial, the majority of patients being White males meant researchers could not do a subgroup analysis looking at ...